Skip to main content
. 2018 Mar 2;15(4):302–313. doi: 10.1177/1479164118759220

Figure 1.

Figure 1.

NFAT inhibition reduces plaque area and degree of stenosis in IGF-II/LDLR–/–ApoB100/100 mice. (a) Study protocol used for all conducted in vivo experiments (both for Study I and II): IGF-II/LDLR–/–ApoB100/100 mice were fed high-fat diet (HFD, 42% of calories from fat and 0.15% from cholesterol) for 8 weeks and received daily i.p. injections of A-285222 (0.29 mg/kg body weight) or vehicle (saline; control) for the last 4 weeks of the HFD period. Arrows indicate the time of the ultrasound biomicroscopy measurements (US) performed in Study II. (b–c) Histologically determined plaque size and degree of stenosis in the brachiocephalic arteries of young (10–16 weeks old) mice. Data represent merged results from Studies I and II, normalized to each control (N = 10 mice/condition, except N = 9 in control females). (d) Representative Elastin van Gieson stained sections from the brachiocephalic artery of young male mice in Study II after treatment with A-285222 or vehicle. Scale bar = 200 µm. (e) Plaque size determined non-invasively by ultrasound biomicroscopy in young mice before and after treatment with A-285222. (f) Change in plaque size from week 4 to week 8 for control and A-285222 treated mice. N = 4–6 mice/group; *p < 0.05.